Trial Profile
Japan working group on The effects of ARBs Selection (Azilsartan vs. Candesartan) on diastolic function in The patients suffering from heart failure with preserved Ejection fraction
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Jan 2022
Price :
$35
*
At a glance
- Drugs Azilsartan (Primary) ; Candesartan cilexetil (Primary)
- Indications Heart failure; Hypertension
- Focus Therapeutic Use
- Acronyms J-TASTE trial
- 09 Jun 2021 Status changed from recruiting to active, no longer recruiting.
- 04 Oct 2016 Status changed from not yet recruiting to recruiting.
- 22 Jun 2016 New trial record